GCG and diabetes mellitus: Commonly administered to individuals with DM, these inhibitors prevent glucose-dependent insulinotropic peptide (GIP) and glucagon-like peptide-1 (GLP-1) from degrading; they thus increase the levels of active hormones, which results in increased glucose-dependent insulin secretion [17].